Walk vascular, LLC, a commercial-stage medical stage medical device company was acquired by global healthcare leader, Abott to introduce a minimally invasive mechanical aspiration thrombectomy system to remove peripheral blood clots.
Abott’s existing endovascular portfolio will be included with Walk vascular’s peripheral thrombectomy systems. The financial terms, however, were not disclosed.
The Senior vice president of Abbott’s vascular business, Julie Tyler said that the acquisition of Walk vascular adapts well into their leading vascular device offerings and drives Abott’s ability to provide unique endovascular therapy solutions to improve patients care.
To improve patient care, Walk vascular’s technology provides physicians with tools to effectively remove dangerous clots from blood vessels.
Unique aspiration systems such as Walk vascular’s JETi peripheral thrombectomy system and next- generation JETi AIO (all in one) peripheral thrombectomy system were developed to remove thrombus, that can reduce blood flow and lead to adverse events in patients.
To remove clots from the peripheral vascular system and also reduce the risk of dislodged clots, the innovative JETi systems were developed. In the JETi registry, walk vascular is presently enrolling up to 250 patients in the United States and Europe.
For aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, both the JETi peripheral thrombectomy systems have received 510 (k) clearance from the US FDA. It has also received clearance from CE Mark in Europe and other countries too.